Driehaus Capital PEPG Position
Active9-Fund ConvergenceDriehaus Capital held their position in PepGen Inc. (PEPG) in Q4 2025, holding $2.1M worth of shares across 315,000 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
PEPG is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for PGN-EDODM1 in 137 days (Aug 31, 2026), making the timing of Driehaus's position particularly relevant.
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
6.2%
5.3 days to cover
Driehaus Capital PEPG Position History
Frequently Asked Questions
Does Driehaus Capital own PEPG?
Yes. As of Q4 2025, Driehaus Capital holds 315,000 shares of PepGen Inc. (PEPG) valued at $2.1M. This data comes from their SEC 13F filing.
How many hedge funds own PEPG?
9 specialist biotech hedge funds currently hold PEPG, including RA Capital Management, Perceptive Advisors, Commodore Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy PEPG?
Driehaus Capital's position in PEPG was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's PEPG position increasing or decreasing?
Driehaus Capital held their PEPG position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PEPGCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →